

To the OMX
Announcement No. 05-08 / Copenhagen, February 26, 2008

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

TopoTarget Announces APO010 Patent Allowed in the USA

Copenhagen, Denmark – February 26, 2008 – TopoTarget A/S (OMX: TOPO) today announced that a patent related to APO010 has been allowed in the United States of America (USA).

APO010 is currently in Phase I trials in patients with refractory solid tumours. Also called a mega-FasLigand, APO010, is a recombinant fusion protein derived from the pro-apoptotic human Fas ligand (FasL) protein, a member of the TNF protein family. APO010 targets Fas receptors (also known as CD95 or Apo1) on the surface of cancer cells, and induces cell death via a mechanism of cell suicide termed apoptosis.

The allowed application US 10/185,425 covers TopoTarget's Megaligand technology whereby members of the tumour necrosis factor family such as FasL can be multimerised into highly active forms. Additionally TopoTarget has been given a patent extension in the US of approximately 15 months which means that the estimated expiry is in 2022. This patent has already been granted in Europe, Australia, Singapore, South Korea and South Africa and is pending in other major territories.

"APO010 provides a completely new mechanism of action in treating cancer, which we are testing in Phase I clinical trials. We are presently escalating the dose to find the right level, and if we reach sufficiently high doses to expect efficacy, we should have very good opportunities for finding a partner for this project," said Peter Buhl Jensen, Chief Executive Officer of TopoTarget A/S. *"This patent is part of our strategy to ensure we have strong patent protection for our broad pipeline of oncology products."*

TopoTarget A/S

For further information, please contact:

Ulla Hald Buhl	Telephone	+45 39 17 83 92
Director IR & Communications	Mobile	+45 21 70 10 49



TopoTarget Announces APO010 Patent Allowed in the USA

Background information

About TopoTarget

TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene[®]/Totect[™] were approved by EMEA in 2006 and the FDA in 2007 and is TopoTarget's first product on the market. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

